[go: up one dir, main page]

WO2008060466A3 - Individualized dosage determination for local administration of therapeutic particles - Google Patents

Individualized dosage determination for local administration of therapeutic particles Download PDF

Info

Publication number
WO2008060466A3
WO2008060466A3 PCT/US2007/023646 US2007023646W WO2008060466A3 WO 2008060466 A3 WO2008060466 A3 WO 2008060466A3 US 2007023646 W US2007023646 W US 2007023646W WO 2008060466 A3 WO2008060466 A3 WO 2008060466A3
Authority
WO
WIPO (PCT)
Prior art keywords
local administration
dosage determination
therapeutic particles
individualized dosage
individualized
Prior art date
Application number
PCT/US2007/023646
Other languages
French (fr)
Other versions
WO2008060466A2 (en
Inventor
Kai Pinkernell
Original Assignee
Cytori Therapeutics Inc
Kai Pinkernell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytori Therapeutics Inc, Kai Pinkernell filed Critical Cytori Therapeutics Inc
Publication of WO2008060466A2 publication Critical patent/WO2008060466A2/en
Publication of WO2008060466A3 publication Critical patent/WO2008060466A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods for intersubject conversion of established dosages of particles, e.g., cells or microparticles, for injection into an affected tissue, e.g., heart, liver, or cancerous tissue. Using these methods, the conversion can be individualized based on the amount of affected tissue in a particular subject.
PCT/US2007/023646 2006-11-10 2007-11-09 Individualized dosage determination for local administration of therapeutic particles WO2008060466A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85816106P 2006-11-10 2006-11-10
US60/858,161 2006-11-10

Publications (2)

Publication Number Publication Date
WO2008060466A2 WO2008060466A2 (en) 2008-05-22
WO2008060466A3 true WO2008060466A3 (en) 2008-08-28

Family

ID=39402210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023646 WO2008060466A2 (en) 2006-11-10 2007-11-09 Individualized dosage determination for local administration of therapeutic particles

Country Status (1)

Country Link
WO (1) WO2008060466A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580678B2 (en) 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device
US10722540B1 (en) 2016-02-01 2020-07-28 The Regents Of The University Of California Microfluidic device and method for shear stress-induced transformation of cells
EP3469374A4 (en) 2016-06-08 2019-12-04 The Regents of the University of California METHOD AND DEVICE FOR TREATING TISSUES AND CELLS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537978B1 (en) * 1996-01-11 2003-03-25 Jagotec Ag Oral administration of effective amounts of forms of hyaluronic acid
US20030125283A1 (en) * 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
US20050079161A1 (en) * 2001-09-30 2005-04-14 Scicotec Gmbh Transluminal application of adult stem cells for body organ tissue repair

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537978B1 (en) * 1996-01-11 2003-03-25 Jagotec Ag Oral administration of effective amounts of forms of hyaluronic acid
US20050079161A1 (en) * 2001-09-30 2005-04-14 Scicotec Gmbh Transluminal application of adult stem cells for body organ tissue repair
US20030125283A1 (en) * 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents

Also Published As

Publication number Publication date
WO2008060466A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2007100901A3 (en) Epinephrine dosing regimens
WO2008085229A3 (en) Cell-based therapies for treating liver disease
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
WO2006076651A3 (en) Treatment method
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP2205257B8 (en) LAG-3Ig (IMP321) dosage regimes for use in the treatment of cancer
EP2526934A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
WO2010036918A3 (en) Intracellular dna receptor
WO2008070047A3 (en) Immunogens in cancer stem cells
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007079190A3 (en) Device and method for enhancing immune response by electrical stimulation
IL185668A0 (en) Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2008121876A3 (en) Non-fucosylated antibodies
WO2008152822A1 (en) Medicinal agent
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2006002102A3 (en) Spirocyclic compounds useful as modulators of nuclear hormone receptor function
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07861897

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07861897

Country of ref document: EP

Kind code of ref document: A2